Search Results
Aug 31, 2026, 10:31 ET Musculoskeletal Pain Market Poised for Transformation During the Forecast Period (2026-2036) as Novel Therapies and Non-Opioid Approaches Reshape Treatment | DelveInsight
promising musculoskeletal pain therapies in clinical trials include Rexlemestrocel-L (MPC-06-ID), TLC599, Lorecivivint (SM04690), CNTX 0066, LTG-321, PCRX-201, PIPE-791, Cebranopadol, and others.Discover musculoskeletal pain clinical trial 2026 update press release @
More news about: DelveInsight Business Research, LLP
Jun 09, 2026, 17:53 ET Pacira BioSciences Announces Stockholders Have Elected All Three of the Company's Director Nominees at Annual Meeting
related clinical trials for EXPAREL, ZILRETTA, iovera° and any of our other product candidates, including but not limited to PCRX-201 (enekinragene inzadenovec) and PCRX-2002; the commercial success of EXPAREL, ZILRETTA and iovera°; the related timing and success of United States Food and Drug Administration
More news about: Pacira BioSciences, Inc.
Jun 05, 2026, 17:41 ET Egan-Jones Recommends Pacira Shareholders Support All Management Nominees
repurchase program authorized in April 2025.Egan-Jones also cites a promising pipeline and stronger board qualifications. ZILRETTA, iovera°, PCRX 201, and PCRX 2002 support a credible path toward reducing reliance on EXPAREL over time, while management's nominees bring public policy, drug development,
More news about: Egan-Jones Ratings Company
Jun 04, 2026, 16:20 ET Pacira BioSciences Reminds Stockholders to Vote the BLUE Proxy Card "FOR" the Election of the Company's Highly Qualified Nominees Ahead of its Annual Meeting
related clinical trials for EXPAREL, ZILRETTA, iovera° and any of our other product candidates, including but not limited to PCRX-201 (enekinragene inzadenovec) and PCRX-2002; the commercial success of EXPAREL, ZILRETTA and iovera°; the related timing and success of United States Food and Drug
More news about: Pacira BioSciences, Inc.
Jun 01, 2026, 16:50 ET Pacira BioSciences Highlights Leading Independent Proxy Advisory Firm ISS' Recommendation to Vote "FOR" All of Pacira's Director Nominees
related clinical trials for EXPAREL, ZILRETTA, iovera° and any of our other product candidates, including but not limited to PCRX-201 (enekinragene inzadenovec) and PCRX-2002; the commercial success of EXPAREL, ZILRETTA and iovera°; the related timing and success of United States Food and Drug
More news about: Pacira BioSciences, Inc.
May 28, 2026, 09:18 ET DOMA PERPETUAL CAPITAL MANAGEMENT QUESTIONS WHY SHAREHOLDERS SHOULD VOTE TO CONTINUE WITH A BOARD THAT HAS OVERSEEN A DECADE OF VALUE DESTRUCTION
(collectively, "DOMA" or "we"), beneficially owns approximately 7.5% of the outstanding shares of common stock of Pacira BioSciences, Inc. (NASDAQ: PCRX) ("Pacira" or the "Company").
More news about: DOMA Perpetual
May 21, 2026, 13:53 ET A LETTER TO PACIRA BIOSCIENCES SHAREHOLDERS FROM DOMA PERPETUAL CAPITAL MANAGEMENT LLC
(collectively, "DOMA" or "we"), beneficially owns approximately 7.5% of the outstanding shares of common stock of Pacira BioSciences, Inc. (NASDAQ: PCRX) ("Pacira" or the "Company"), has today sent a letter to the Company's stockholders.
More news about: DOMA Perpetual
May 20, 2026, 12:28 ET DOMA Perpetual Director Nominees Send Letter to Shareholders of Pacira Biosciences
(collectively "DOMA" or "we"), beneficially owns approximately 7.5% of the outstanding shares of common stock of Pacira BioSciences, Inc. (NASDAQ: PCRX) ("Pacira" or the "Company") announced that the two independent, highly qualified members of DOMA's three-person slate of nominees for election to the
More news about: DOMA Perpetual
May 13, 2026, 10:58 ET DOMA Perpetual Issues & Mails Letter to Shareholders of Pacira BioSciences - Along with its Definitive Proxy Statement & WHITE Proxy Card - Urging Shareholders to Vote "FOR" DOMA's Three Highly Qualified, Independent Board Candidates
BioSciences, Inc. (PCRX) ("Pacira" or the "Company"), a drug manufacturer that is falling well short of its potential and is in urgent need of a new direction.DOMA Perpetual Capital Management LLC, together with its affiliates ("DOMA") currently beneficially owns approximately 7.5% of PCRX common shares.
More news about: DOMA Perpetual
Mar 12, 2026, 08:20 ET DOMA Perpetual Nominates Three Highly Qualified Candidates for the Board of Pacira BioSciences, Inc.
affiliates (collectively "DOMA" or "we"), beneficially owns approximately 7.3% of the outstanding shares of common stock of Pacira BioSciences (NASDAQ: PCRX) ("Pacira" or the "Company").[iv]
More news about: DOMA Perpetual
Mar 11, 2026, 13:06 ET DOMA Perpetual Nominates Three Highly Qualified Candidates for the Board of Pacira BioSciences, Inc.
affiliates (collectively "DOMA" or "we"), beneficially owns approximately 7.1% of the outstanding shares of common stock of Pacira BioSciences (NASDAQ: PCRX) ("Pacira" or the "Company").iv
More news about: DOMA Perpetual
Dec 30, 2025, 10:41 ET DOMA Perpetual Capital Management Announces Intent to Nominate Three Highly Qualified, Independent Director Candidates at 2026 Annual Meeting of Pacira BioSciences, Inc.
its affiliates, "DOMA"), which beneficially owns approximately 6.83% of the outstanding shares of Common Stock of Pacira BioSciences, Inc. (NASDAQ: PCRX) ("Pacira" or the "Company"), today announced that it intends to nominate three highly-qualified, independent director candidates at the Company's 2026
More news about: DOMA Perpetual
Nov 10, 2025, 20:09 ET DOMA Perpetual Sends Letter Calling for the Board of Directors of Pacira BioSciences, Inc. to Immediately Explore a Sale of the Business
Nov. 10, 2025 /PRNewswire/ -- DOMA Perpetual Capital Management LLC, a significant stockholder of Pacira BioSciences, Inc. (NASDAQ: PCRX) ("Pacira"), today sent a letter to the Board of Directors of Pacira (the "Board") urging the Board to hire bankers and conduct a full sale process
More news about: DOMA Perpetual